Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1

doi:10.1111/ejn.15502

Review

. 2021 Nov;54(10):7749-7769.

doi: 10.1111/ejn.15502. Epub 2021 Nov 7.

Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1

Xiao-Yu Liu¹, Ni Zhang¹, Sheng-Xiao Zhang^{2

3}, Ping Xu¹

Affiliations

¹ Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
² Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
³ Key laboratory of Cellular Physiology, Shanxi Medical University, Ministry of Education, Shanxi, China.

PMID: 34676939
DOI: 10.1111/ejn.15502

Review

Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1

Xiao-Yu Liu et al. Eur J Neurosci. 2021 Nov.

. 2021 Nov;54(10):7749-7769.

doi: 10.1111/ejn.15502. Epub 2021 Nov 7.

Authors

Xiao-Yu Liu¹, Ni Zhang¹, Sheng-Xiao Zhang^{2

3}, Ping Xu¹

Affiliations

¹ Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
² Department of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
³ Key laboratory of Cellular Physiology, Shanxi Medical University, Ministry of Education, Shanxi, China.

PMID: 34676939
DOI: 10.1111/ejn.15502

Abstract

Increasing evidence shows a close relationship between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Recently, glucagon-like peptide-1 (GLP-1), a gut incretin hormone, has become a well-established treatment for T2DM and is likely to be involved in treating cognitive impairment. In this mini review, the similarities between AD and T2DM are summarised with the main focus on GLP-1-based therapeutics in AD.

Keywords: Alzheimer's disease; glucagon-like peptide-1; learning and memory; neuroprotection; type 2 diabetes mellitus.

PubMed Disclaimer

Cited by

Clinical antidiabetic medication used in Alzheimer's disease: From basic discovery to therapeutics development.
Huang J, Huang N, Cui D, Shi J, Qiu Y. Huang J, et al. Front Aging Neurosci. 2023 Feb 10;15:1122300. doi: 10.3389/fnagi.2023.1122300. eCollection 2023. Front Aging Neurosci. 2023. PMID: 36845652 Free PMC article. Review.
Type 2 Diabetes and Alzheimer's Disease: The Emerging Role of Cellular Lipotoxicity.
Marrano N, Biondi G, Borrelli A, Rella M, Zambetta T, Di Gioia L, Caporusso M, Logroscino G, Perrini S, Giorgino F, Natalicchio A. Marrano N, et al. Biomolecules. 2023 Jan 16;13(1):183. doi: 10.3390/biom13010183. Biomolecules. 2023. PMID: 36671568 Free PMC article. Review.
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease.
Du H, Meng X, Yao Y, Xu J. Du H, et al. Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi: 10.3389/fendo.2022.1033479. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36465634 Free PMC article. Review.
Implications of Microorganisms in Alzheimer's Disease.
Yadav P, Lee YH, Panday H, Kant S, Bajwa N, Parashar R, Jha SK, Jha NK, Nand P, Lee SS, Jha AK. Yadav P, et al. Curr Issues Mol Biol. 2022 Sep 30;44(10):4584-4615. doi: 10.3390/cimb44100314. Curr Issues Mol Biol. 2022. PMID: 36286029 Free PMC article. Review.
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents.
Zhu S, Bai Q, Li L, Xu T. Zhu S, et al. Comput Struct Biotechnol J. 2022 Jun 1;20:2839-2847. doi: 10.1016/j.csbj.2022.05.057. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 35765655 Free PMC article. Review.

References

REFERENCES

1. Abbas, T., Faivre, E., & Hölscher, C. (2009). Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behavioural Brain Research, 205(1), 265-271.
1. Ahn, K. C., Learman, C. R., Baker, G. B., Weaver, C. L., Chung, P. S., Kim, H. G., & Song, M. S. (2019). Regulation of diabetes: A therapeutic strategy for Alzheimer's disease? Journal of Korean Medical Science, 34(46), e297.
1. Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., Kobayashi, D. (2020). Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. American Journal of Alzheimer's Disease and other Dementias, 35, 1533317519899546.
1. Arastoo, M., Lofthouse, R., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020). Current progress and future directions for tau-based fluid biomarker diagnostics in Alzheimer's disease. International Journal of Molecular Sciences, 21(22), 8673.
1. Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., Holtzman, D. M., & Nathan, D. M. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nature Reviews Neurology, 14(3), 168-181.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] Abbas, T., Faivre, E., & Hölscher, C. (2009). Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behavioural Brain Research, 205(1), 265-271.

[2] Abbas, T., Faivre, E., & Hölscher, C. (2009). Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease. Behavioural Brain Research, 205(1), 265-271.

[3] Ahn, K. C., Learman, C. R., Baker, G. B., Weaver, C. L., Chung, P. S., Kim, H. G., & Song, M. S. (2019). Regulation of diabetes: A therapeutic strategy for Alzheimer's disease? Journal of Korean Medical Science, 34(46), e297.

[4] Ahn, K. C., Learman, C. R., Baker, G. B., Weaver, C. L., Chung, P. S., Kim, H. G., & Song, M. S. (2019). Regulation of diabetes: A therapeutic strategy for Alzheimer's disease? Journal of Korean Medical Science, 34(46), e297.

[5] Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., Kobayashi, D. (2020). Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. American Journal of Alzheimer's Disease and other Dementias, 35, 1533317519899546.

[6] Akimoto, H., Negishi, A., Oshima, S., Wakiyama, H., Okita, M., Horii, N., Inoue, N., Ohshima, S., Kobayashi, D. (2020). Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. American Journal of Alzheimer's Disease and other Dementias, 35, 1533317519899546.

[7] Arastoo, M., Lofthouse, R., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020). Current progress and future directions for tau-based fluid biomarker diagnostics in Alzheimer's disease. International Journal of Molecular Sciences, 21(22), 8673.

[8] Arastoo, M., Lofthouse, R., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020). Current progress and future directions for tau-based fluid biomarker diagnostics in Alzheimer's disease. International Journal of Molecular Sciences, 21(22), 8673.

[9] Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., Holtzman, D. M., & Nathan, D. M. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nature Reviews Neurology, 14(3), 168-181.

[10] Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., Holtzman, D. M., & Nathan, D. M. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nature Reviews Neurology, 14(3), 168-181.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1

Affiliations

Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical